Susquehanna International Group’s Centessa Pharmaceuticals CNTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.89M Buy
173,400
+76,700
+79% +$1.96M ﹤0.01% 3699
2025
Q4
$2.42M Buy
96,700
+19,000
+24% +$481K ﹤0.01% 5246
2025
Q3
$1.88M Buy
77,700
+8,700
+13% +$155K ﹤0.01% 5926
2025
Q2
$907K Buy
69,000
+12,300
+22% +$156K ﹤0.01% 7684
2025
Q1
$815K Buy
+56,700
New +$928K ﹤0.01% 7776
2024
Q4
Sell
-23,500
Closed -$376K 12312
2024
Q3
$376K Buy
+23,500
New +$288K ﹤0.01% 9119

Other funds holding CNTA

Susquehanna International Group's CNTA Position: Q1 2026 in Review

Susquehanna International Group increased its Centessa Pharmaceuticals (CNTA) stake by 53% in Q1 2026, buying an estimated $158K and bringing the position to 17,737 shares worth $705K. The position accounts for ﹤0.01% of the portfolio, ranked #8799.

Susquehanna International Group first reported a position in CNTA in Q1 2023 and has held it in 6 quarters since. The position peaked at $12.9M in Q1 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Susquehanna International Group held 17,737 shares of Centessa Pharmaceuticals worth $705K as of Q1 2026.
  • Susquehanna International Group bought 6,174 Centessa Pharmaceuticals shares in Q1 2026, an estimated $158K.
  • Centessa Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8799 holding.
  • Susquehanna International Group first reported a position in Centessa Pharmaceuticals in Q1 2023 and has held it in 6 quarters since.
  • Susquehanna International Group's Centessa Pharmaceuticals position peaked at $12.9M in Q1 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.